2010
DOI: 10.1200/jco.2009.23.8329
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: In older adult patients with low marrow blast count (20% to 30%) WHO-defined AML, azacitidine significantly prolongs OS and significantly improves several patient morbidity measures compared with CCR.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

22
656
5
18

Year Published

2011
2011
2020
2020

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 871 publications
(701 citation statements)
references
References 41 publications
22
656
5
18
Order By: Relevance
“…A focus on whether the difference is "statistically significant" (P 5 0.037 on an unplanned analysis after the planned number of events had occurred) loses sight of the unsatisfactory results in both arms, with patients losing >90% of their normally remaining life expectancy. An analogous trial involving azacitidine leads to the same conclusion [42]. Thus a fundamental question is whether results with either drug can be improved.…”
Section: Azacitidine and Decitabinementioning
confidence: 81%
“…A focus on whether the difference is "statistically significant" (P 5 0.037 on an unplanned analysis after the planned number of events had occurred) loses sight of the unsatisfactory results in both arms, with patients losing >90% of their normally remaining life expectancy. An analogous trial involving azacitidine leads to the same conclusion [42]. Thus a fundamental question is whether results with either drug can be improved.…”
Section: Azacitidine and Decitabinementioning
confidence: 81%
“…In total 7 patients with MDS or CMML and 2 patients with AML receiving CC‐486 monotherapy in this study attained CR or PR, including, importantly, patients for whom previous DNMTi therapy had failed. While multiple studies have shown injectable azacitidine can improve OS in higher‐risk MDS and AML without requiring CR5, 7, 8, 9, 37; the effect of CC‐486 on OS has not yet been reported and was not captured in this phase 1 study, but is under investigation in an ongoing phase 3 trial of CC‐486 in patients with MDS (NCT01566695).…”
Section: Discussionmentioning
confidence: 99%
“…Hypomethylating agents (HMAs) show activity in patients with AML 4, 5, 6. However, the short plasma half‐life of S‐phase–dependent drugs such as decitabine and 5‐azacitidine limits their incorporation into the DNA of replicating leukemia cells.…”
Section: Introductionmentioning
confidence: 99%